Back to Awarded Treatment Trials
Awarded Trial: 07TGS-1082
Grant ID
07TGS-1082
Illness
Schizophrenia
Primary Drug/Intervention
Cannabidiol
Primary Dosage
600 mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Ranganathan
Sample Size
36
Duration of Study Period for Each Subject
42 days
Outcome Measurements
PANSS, MATRICS Consensus Cognitive Battery, HVLT, BMI, VAS
Results
This study randomized 36 patients with schizophrenia or schizoaffective disorder, stabilized on anti-psychotics, between the ages of 18-65, to add-on 600 mg/day cannibidiol or placebo for six weeks. No improvement in verbal short-term memory was detected by HVLT Total Immediate Recall, and no improvement in attention or cognition was detected by MATRICS Cognitive Consensus Battery (MCCB). There were no significant effects on smoking, movement, or depression.
Publication
N/A
Link
N/A
PI Name
Mohini Ranganathan
Degree
MD
Center
VACHS
Institution
Yale University
Address
950 Campbell Ave, Department of Psychiatry
City or Town
West Haven
State or Province
CT
Zip or Postal Code
6516
Country
USA
Email Address
mohini.ranganathan@yale.edu